>Any chance that Tekmira will receive substantial cash ... in addition to reclaiming dominion over their >intellectual property? ... or perhaps cash and more Alnylam targets?
Yes, that's possible. But it will all depend how much evidence they have and what risk alnylam is willing to take. Cash is just only part of the settlement/lawsuit. There are many other things that can be considered like royalties, milestones, manufacturing agreements.
I wouldn't expect alny to give up a serious amount without trying to get a new (exclusive) license. If they don't want to pay upfront they can hide more of the cash in milestones and royalties. Or in a manufacturing agreement.
I'm not sure tkmr would want more picks right now. They already got more than they can handle.
Based on the lawsuit so far I would expect a settlement for anywhere in between 30-120 million in cash
>>Btw ... in regards to Alnylam targets ... what other targets are available? Some of Tekmira's selections seem a bit weak, but perhaps the inventory is slim to begin with?
I think you are right that the number of great picks may be somewhat limited. Remember that alny already has sold their best targets to partners like roche, novartis, takeda. Plus they probably have a few good ones too for internal development. And of course, they probably only want targets in the liver right now.
On the other hand I don't think tekmira can both develop the delivery technology and go after some big markets. This is just a small company and only needs to show their delivery tech works and can hit more targets. If they bring a few small drugs to market that would be more than enough for a company this size. Just look at alny right now, they have lots of cash and only can do 1 program in TTR, not a big market either.